Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2006

Sade Revital Bruchim Bar, Chetrit Angela, Figer Arie, Papa Moshe Z, Flex Dov, Rizel Shulamit, Friedman Eitan

Abstract excerpt

The aim of this study was to compare reproductive factors, use of oral contraceptives (OC) and hormone replacement therapy (HRT) in consecutive Jewish Ashkenazi breast cancer patients, with and without BRCA1/BRCA2 mutations. Jewish Israeli women with breast cancer (n=385) were genotyped for the t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, BRCA1
Share to Breast Neoplasms
Share to Contraceptives, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Heterozygote

Share to Hormone Replacement Therapy

Share to Regression Analysis

Source

Identifiers

PMID: 16464572
DOI: 10.1016/j.ejca.2005.08.045

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16464572-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.PMID 16464572Read ↗

Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.Semantic proximity Read ↗

Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.Semantic proximity Read ↗

BRCA1/BRCA2 mutations and breast cancer in Ashkenazi Jewish women.Semantic proximity Read ↗

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.Semantic proximity Read ↗

Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.Semantic proximity Read ↗

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.Semantic proximity Read ↗

Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States).Semantic proximity Read ↗

Hereditary breast cancer in Jews.Semantic proximity Read ↗

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.Semantic proximity Read ↗

Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.Semantic proximity Read ↗

Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?Semantic proximity Read ↗

Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.